Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
Clinical trial NCT06839560 · RECRUITING
Trial details
- NCT number
- NCT06839560
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2028-09-10
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.